Overview

Pegfilgrastim for Stem Cell Mobilization in Children (Meg-5)

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Hypothesis : pegfilgrastim at 200 µg/kg between 12 and 18 days after previous chemotherapy provides an efficient stem cell mobilization in children with malignancies Design: phase 2 study. Judgment criterion: percentage of children achieving at least 5x10e6 CD34 cells with a standard apheresis (less than 3 blood volume processed
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital, Clermont-Ferrand
Collaborator:
Amgen